Effects of befloxatone, a reversible selective monoamine oxidase-A inhibitor, on psychomotor function and memory in healthy subjects

Journal of Clinical Pharmacology

Volumn 36, Issue 10, 1996, Pages 942-950

  Warot, Dominique ^a   Berlin, Ivan ^a   Patat, Alain ^b   Durrieu, Geneviève ^b   Zieleniuk, Isabelle ^b   Puech, Alain J ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BEFLOXATONE; MONOAMINE OXIDASE INHIBITOR; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COMPETITIVE INHIBITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; HUMAN; INFORMATION PROCESSING; LONG TERM MEMORY; MALE; MEMORY; MIOSIS; ORAL DRUG ADMINISTRATION; PSYCHOMOTOR ACTIVITY; PUPILLOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SELF CONCEPT;

EID: 0029843570     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04762.x     Document Type: Article

References (56)

1. U'Prichard DC, Greenberg DA, Sheehan DA, Snyder SA: Tricyclic antidepressants: therapeutic properties and affinity for alpha-noradrenergic receptor binding sites in the brain. Science 1978; 199:197-199.
2. Schwartz JC: Histamine receptors in brain. Life Sci 1979; 25: 895-912.
3. Bye C, Clubley M, Peck AW: Drowsiness, impaired performance and tricyclic antidepressant drugs. Br J Clin Pharmacol 1978; 6:155-161.
4. Hindmarch I, Harrison C: The effects of paroxetine and other antidepressants in combination with alcohol in psychomotor activity related to car driving. Hum Psychopharmacol 1988; 3:13-20.
5. Linnoila M, Johnson J, Dubyoski K, Buchsbaum MS, Schneinin M, Kilts C: Effects of antidepressants on skilled performance. Br J Clin Pharmacol 1984; 18(Suppl):109S-120S.
6. Thompson PJ, Trimble MR: Non-monoamineoxidase inhibitor antidepressant drugs and cognitive functions: a review. Psychol Med 1982; 12:539-548.
7. Deptula D, Pomara N: Effects of antidepressants on human performance: a review. J Clin Psychopharmacol 1990; 10:105-111.
8. Siegfried K, O'Connolly M: Cognitive and psychomotor effects of different antidepressants in the treatment of old age depression. Int Clin Psychopharmacol 1986; 1:231-243.
9. Thompson PJ: Antidepressants and memory: a review. Hum Psychopharmacol 1991; 6:79-90.
10. Lemberger L, Rowe H, Bergstrom RF, Farid KZ, Enas GG: Effect of fluoxetine on psychomotor performance, physiologic response, and kinetics of ethanol. Clin Pharmacol Ther 1985; 37:658-664.
11. Kerr JS, Sherwood N, Hindmarch I: The comparative psychopharmacology of 5HT reuptake inhibitors. Hum Psychopharmacol 1991; 6:313-317.
12. Curran HV, Lader M: The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects. Eur J Clin Pharmacol 1986; 29:601-607.
13. Hindmarch I, Bhatti JZ: Psychopharmacological effects of sertraline in normal, healthy volunteers. Eur J Clin Pharmacol 1988; 35:221-223.
14. Kerr JS, Fairweather DB, Mahendran R, Hindmarch I: The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly. Int Clin Psychopharmacol 1992; 7:101-108.
15. Finberg JPM, Youdim MBH: Reversible monoamine oxidase inhibitors and the cheese effect. In, Tipton KF, Dostert P, Strolin Benedetti M (eds.): Monoamineoxidase and Disease: Prospects for Therapy with Reversible Inhibitors. London: Academic Press, 1984; 479-485.
16. Baldessarini RJ: Drugs and the treatment of psychiatric disorders. In, Goodman Gilman A, Rall TW, Nies AS, Taylor P (eds.): The Pharmacological Basis of Therapeutics. Oxford: Pergamon Press, 1990; 383-435.
17. Georgortas A, Reisberg B, Ferris S: First results on the effects of MAO inhibitor on cognitive functioning in elderly depressed patients. Arch Gerontol Geriatr 1983; 2:249-254.
18. Raskin A, Friedman AS, Dimascio A: Effects of chlorpromazine, imipramine, diazepam and phenelzine on psychomotor and cognitive skills of depressed patients. Psychopharmacol Bull 1983; 19:649-652.
19. Bieck PR, Antonin KH: Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol 1988; 8:237-245.
20. Berlin I, Zimmer R, Cournot A, Payan C, Pedarriosse AM, Puech AJ: Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther 1989; 46: 344-351.
21. Bieck PR, Firkusny L, Schick C, Eng C, Antonin KH, Nilsson E, et al: Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clin Pharmacol Ther 1989; 45:260-269.
22. Simpson GM, Gratz SS: Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers. Clin Pharmacol Ther 1992; 52:286-291.
23. Patat A, Berlin I, Durrieu G, Armand P, Fitoussi S, Molinier P, Caille P: Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects. J Clin Pharmacol 1995; 35:633-643.
24. Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ: Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol 1990; 30:805-816.
25. Hindmarch I, Kerr J: Behavioral toxicity of antidepressants with particular reference to moclobemide. Psychopharmacology 1992; 106:549-555.
26. Ramaekers JG, Swijgman HF, O'Hanlon JF: Effects of moclobemide and mianserin of highway driving, psychometric performance and subjective parameters, relative to placebo. Psychopharmacology 1992; 106(Suppl):S62-S67.
27. Rovei V, Caille D, Curet O, Ego D, Jarreau FX: Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor. J Neural Transm 1994; 41:339-347.
28. Ansseau M, Caille P, Derks C, Cierin-Puiseux I, Wauthy J, Ego D, et al: Phase I study of single ascending doses of befloxatone, a new reversible MAO-A inhibitor antidepressant (abstract). Clin Neuropharmacol 1992; 15(Suppl 1):328B.
29. Hindmarch I, Subhan Z: The effects of antidepressants taken with and without alcohol on information processing, psychomotor performance and car handling ability. In. O'Hanlon JF, de Gier JJ (eds.): Drugs and Driving. London: Taylor & Francis, 1986; 231-258.
30. Hindmarch I: Three antidepressants (amitriptyline, dothiepin, fluoxetine), with and without alcohol, compared with placebo on tests of psychomotor ability related to car driving. Hum Psychopharmacol 1987; 2:177-183.
31. Hindmarch I, Harrison C, Shillingford CA: An investigation of the effects of lofepramine, nomifensine, amitriptyline and placebo on aspects of memory and psychomotor performance related to car driving. Int Clin Psychopharmacol 1988; 3:157-165.
32. Wilson WH, Higano H, Papadatos Y, Kelwala S, Ban TA: A double-blind placebo-controlled study to compare the autonomie effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers. Br J Clin Pharmacol 1983; 15(Suppl):385S-392S.
33. Hindmarch I: Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980; 10:189-209.
34. Warot D, Krebs MO, Bensimon G, Payan C, Danjou P, Lacomblez L, Puech AJ: Dose-effect study of levomepromazine on psychomotor and memory tasks in healthy volunteers. Hum Psychopharmacol 1987; 3:127-132.
35. Bond A, Lader M: The use of the analogue scales in rating subjective feelings. Br J Med Psychol 1974; 47:211-218.
36. Haertzen CA: Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI). Psychol Rep 1966; 18:163-164.
37. Haertzen CA, Hill HE, Belleville RE: Development of the Addiction Research Center Inventory (ARCI): selection of items that are sensitive to the effects of various drugs. Psychopharmacologia 1963; 4:155-166.
38. Martin WR, Sloan JW, Sapira JD, Jasinski DR: Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 1971; 12:245-258.
39. Cann-Moisan C, Caroff J, Le Bras P, Girin E, Curet O, Gandon JM: Automated measurement of dihydrophenylglycol (DHPG) in plasma by high performance liquid chromatography with electrochemical detection. J Chromatogr (in press).
40. Ascalone V, Dalbo L: Determination of amitriptyline, chlorimipramine and their demethylated metabolites in plasma by normal phase HPLC and UV detection. In, Piemonte G, Tagliaro F, Marigo M, Frigerio A (eds.): Development in Analytical Methods in Pharmaceutical, Biochemical, and Forensic Sciences. New York: Plenum Publishing Corporation, 1987; 233-239.
41. Hommel G: A comparison of two modified Bonferroni procedures. Biometrika 1989; 76:624-625.
42. Wright SP: Adjusted P-values for simultaneous inference. Biometrics 1992; 48:1005-1013.
43. Patat A, Gandon JM, Durrieu G, Le Coz F, Curet O, Cimarosti I, Allain H: Effects of single and multiple doses of a new reversible MAO-A inhibitor, befloxatone, on psychomotor performance and memory in healthy subjects. Hum Psychopharmacol 1995; 10:111-125.
44. Allain H, Lieury A, Brunet-Bourgin F, Mirabaud C, Trebon P, Le Coz F, Gandon JM; Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline. Psychopharmacology 1992; 106(Suppl):S56-S61.
45. Stern KN, Chait LD, Johanson CE: Reinforcing and subjective effects of caffeine in normal human volunteers. Psychopharmacology 1989; 98:81-88.
46. Evans SM, Bunderburk FR, Griffiths RR: Zolpidem and triazolam in humans: behavioural and subjective effects and abuse liability. J Pharmacol Exp Ther 1990; 255:1246-1255.
47. Chait LD: Factors influencing the subjective response to caffeine. Behav Pharmacol 1992; 3:219-228.
48. Mattila MJ, Liljequist R, Seppala T: Effects of amitriptyline and mianserin on psychomotor skills and memory in man. Br J Clin Pharmacol 1978; 5(Suppl):53S-55S.
49. Curran HV, Sakulsriprong M, Lader M: Antidepressants and human memory: an investigation of four drugs with different sedative and anticholinergic profiles. Psychopharmacology 1988; 95: 520-527.
50. Kopera H: Anticholinergic and blood pressure: effects of mianserin, amitriptyline and placebo. Br J Clin Pharmacol 1978; 5: 29S-34S.
51. Peck AW, Bye CE, Clubley M, Henson T, Riddington C: A comparison of bupropion hydrochloride with dexamphetamine and amitriptyline in healthy subjects. Br J Clin Pharmacol 1979; 7:469-478.
52. Szabadi E, Gaszner P, Bradshaw CM: Interaction of desipramine and amitriptyline with adrenergic mechanisms in the human iris in vivo. Eur J Clin Pharmacol 1981; 19:403-408.
53. Warrot D, Molinier P, Lacomblez L, Payan C, Danjou Ph, Puech AP: Dose related effects of trimipramine on psychomotor function, memory, and autonomie nervous system activity in healthy volunteers. Hum Psychopharmacol 1988; 4:121-127.
54. Hoyng FJ, van Alphen GWHM: Behaviour of IOP and pupil size after topical tranylcypromine in the rabbit eye. Doc Ophthalmol 1981; 51:225-234.
55. Grünberger J, Linzmayer L, Cepko H, Saletu B: Lichtevozierte dynamische Pupillometrie zur Differenzierurg psychotroper Substanzen. Arzneinmittelforschung 1987; 37:357-360.
56. Ziegler VE, Biggs JT, Ardekani AB, Rosen SH: Contribution to the pharmacokinetics of amitriptyline. J Clin Pharmacol 1978: 462-467.